WSIS2016: Software Licensing Matters – To Everybody 02/05/2016 by Monika Ermert for Intellectual Property Watch 1 Comment A special committee at the World Intellectual Property Organisation on software licensing, a globally harmonized software licence model and a dispute resolution system were among the ideas presented to the World Intellectual Property Organization (WIPO) at panel it hosted at day one of the 2016 WSIS Forum meeting in Geneva.
MSF Issues In-Depth Report On R&D And Drug Prices 02/05/2016 by Intellectual Property Watch 3 Comments Médecins Sans Frontières (MSF, Doctor Without Borders) today announced a report detailing what it calls failings in the current system for developing new drugs in ways that all patients can afford and access, and providing proposed policy options for addressing the problems.
Special Report: The Battle For Biosimilars In India 02/05/2016 by Patralekha Chatterjee for Intellectual Property Watch 1 Comment [story updated] Biosimilar drugs hold out big opportunities for India’s drug companies. But the future is fraught with challenges. One key challenge is regulations. What does this mean for countries like India, an emerging market for biosimilars? How will the evolving global regulatory environment on biosimilars impact patients? Last month, both these questions came to the fore as the battle over biosimilars moved centre stage in this country in the wake of an interim order by the Delhi High Court, and then another decision by a Division Bench of the same court which took a different view.